Predictive factors for failure of neoadjuvant docetaxel, cisplatin, and 5-fluorouracil therapy in esophageal squamous cell carcinoma
Diseases of the Esophagus · 2025
DOI: 10.1093/dote/doae115 ↗Kurz gefasst
Fachartikel in der Zeitschrift Diseases of the Esophagus, 2025. Verfasst von Masayoshi Terayama und 13 weiteren Autor:innen. Beteiligte Einrichtung: Department of Gastroenterological Surgery, Cancer Institute Hospital, Japanese Foundation for Cancer Research, Tokyo, Japan. Hauptthemen laut MEDLINE: Fluorouracil, Cisplatin, Docetaxel, Neoadjuvant Therapy. Die Arbeit nennt 41 Literaturangaben.
Abstract (Originalsprache)
Recently, neoadjuvant chemotherapy comprising docetaxel, cisplatin, and 5-fluorouracil showed promising efficacy for esophageal squamous cell carcinoma. However, some patients do not achieve curative resection despite neoadjuvant chemotherapy using these drugs. This study aimed to clarify the pretherapeutic characteristics of these patients. We included 113 patients who underwent neoadjuvant chemotherapy with docetaxel, cisplatin, and 5-fluorouracil for potentially resectable esophageal squamous cell carcinoma and compared the clinical characteristics between patients who achieved curative resection (curative group) and those who failed to achieve curative resection after planned neoadjuvant chemotherapy (noncurative group). Moreover, we determined the factors predicting noncurative outcomes. Ninety-one (81%) and 22 patients (19%) were in the curative and noncurative groups, respectively. The noncurative group had significantly more tumors located in the upper third of the esophagus, larger-sized tumors, and borderline resectable tumors than the curative group (P = 0.003, 0.049, and <0.001, respectively). Moreover, the noncurative group had significantly higher serum squamous cell carcinoma antigen concentrations than the curative group (P = 0.008). Multivariable analysis identified tumor location in the upper third of the esophagus (odds ratio 7.31, P = 0.002), tumor size ≥50 mm (odds ratio 4.71, P = 0.037), and borderline resectable tumors (odds ratio 6.65, P = 0.003) as independent predictors for noncurative outcomes. Tumor location in the upper third of the esophagus, larger-sized tumors, and borderline resectable tumors might be significant predictors for noncurative outcomes in patients who received neoadjuvant chemotherapy with docetaxel, cisplatin, and 5-fluorouracil.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Gastroenterological Surgery, Cancer Institute Hospital, Japanese Foundation for Cancer Research, Tokyo, Japan.
- Department of Gastroenterological Chemotherapy, Cancer Institute Hospital, Japanese Foundation for Cancer Research, Tokyo, Japan.
ORCID-Profile: Akihiko Okamura
Zitieren
APA
Terayama, M., Okamura, A., Oki, A., Kuriyama, K., Takahashi, N., Tamura, M., Kanamori, J., Udagawa, S., Shimozaki, K., Osumi, H., Fukuoka, S., Ogura, M., Chin, K., & Watanabe, M. (2025). Predictive factors for failure of neoadjuvant docetaxel, cisplatin, and 5-fluorouracil therapy in esophageal squamous cell carcinoma. Diseases of the Esophagus. https://doi.org/10.1093/dote/doae115
Vancouver
Terayama M, Okamura A, Oki A, Kuriyama K, Takahashi N, Tamura M, et al. Predictive factors for failure of neoadjuvant docetaxel, cisplatin, and 5-fluorouracil therapy in esophageal squamous cell carcinoma. Diseases of the Esophagus. 2025. doi:10.1093/dote/doae115
BibTeX
@article{Terayama2025,
author = {Terayama, Masayoshi and Okamura, Akihiko and Oki, Akira and Kuriyama, Kengo and Takahashi, Naoki and Tamura, Masahiro and Kanamori, Jun and Udagawa, Shohei and Shimozaki, Keitaro and Osumi, Hiroki and Fukuoka, Shota and Ogura, Mariko and Chin, Keisho and Watanabe, Masayuki},
title = {Predictive factors for failure of neoadjuvant docetaxel, cisplatin, and 5-fluorouracil therapy in esophageal squamous cell carcinoma},
journal = {Diseases of the Esophagus},
year = {2025},
doi = {10.1093/dote/doae115}
}
EUVIMED